Medartis Holding AG
Medartis Holding AG Fundamental Analysis
Medartis Holding AG (MED.SW) shows weak financial fundamentals with a PE ratio of 121.51, profit margin of 3.10%, and ROE of 3.11%. The company generates $0.3B in annual revenue with moderate year-over-year growth of 6.05%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 37.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze MED.SW's fundamental strength across five key dimensions:
Efficiency Score
WeakMED.SW struggles to generate sufficient returns from assets.
Valuation Score
ModerateMED.SW shows balanced valuation metrics.
Growth Score
ModerateMED.SW shows steady but slowing expansion.
Financial Health Score
ExcellentMED.SW maintains a strong and stable balance sheet.
Profitability Score
WeakMED.SW struggles to sustain strong margins.
Key Financial Metrics
Is MED.SW Expensive or Cheap?
P/E Ratio
MED.SW trades at 121.51 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, MED.SW's PEG of 0.07 indicates potential undervaluation.
Price to Book
The market values Medartis Holding AG at 3.68 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 34.76 times EBITDA. This signals the market has high growth expectations.
How Well Does MED.SW Make Money?
Net Profit Margin
For every $100 in sales, Medartis Holding AG keeps $3.10 as profit after all expenses.
Operating Margin
Core operations generate 0.42 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $3.11 in profit for every $100 of shareholder equity.
ROA
Medartis Holding AG generates $1.49 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Medartis Holding AG produces operating cash flow of $32.81M, showing steady but balanced cash generation.
Free Cash Flow
Medartis Holding AG produces free cash flow of $14.14M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $1.14 in free cash annually.
FCF Yield
MED.SW converts 1.39% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
121.51
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.07
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.68
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.77
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.57
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.21
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.03
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.002
vs 25 benchmark
How MED.SW Stacks Against Its Sector Peers
| Metric | MED.SW Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 121.51 | 28.54 | Worse (Expensive) |
| ROE | 3.11% | 738.00% | Weak |
| Net Margin | 3.10% | -43982.00% (disorted) | Weak |
| Debt/Equity | 0.57 | 0.34 | Weak (High Leverage) |
| Current Ratio | 2.21 | 2806.01 | Strong Liquidity |
| ROA | 1.49% | -14624.00% (disorted) | Weak |
MED.SW outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Medartis Holding AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
63.87%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
55.91%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
229.36%
Industry Style: Defensive, Growth, Innovation
High Growth